For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$54.07
Thesis
Moderna is a pure-play mRNA platform company. The COVID franchise that funded the build-out is running off, and the equity case now depends on translating the platform into a durable pipeline — RSV, flu combinations, personalized cancer vaccines with Merck, and rare-disease programs.
The platform thesis is real, but cash burn against a shrinking COVID base means the next two years are about pipeline readouts and disciplined cost control rather than top-line growth.
Catalysts
- Personalized cancer vaccine (INT) phase 3 progress with Merck
- Flu and COVID-flu combination approvals and uptake
- Rare-disease readouts validating the broader platform
- Operating-cost reductions stabilizing the cash runway
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 8LeadershipSEC
8-K filing (items 5.02,7.01,9.01) disclosing officer or director changes.